<DOC>
	<DOC>NCT01956201</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Atorvastatin and Fenofibrate compared with atorvastatin monotherapy in mixed hypercholesterolemic patients.</brief_summary>
	<brief_title>Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin</brief_title>
	<detailed_description>Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study Primary Outcome Measure: The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8] Secondary Outcome Measures: The achievement rate of LDL-C&lt;100mg/dl, Non-HDL-C&lt;130mg/dl [Time Frame: from baseline at week 8] The mean percent change of LDL-C, HDL-C, TG, TC, Apo-AI, Apo-B [Time Frame: from baseline at week 4, 8] The mean percent change of Non-LDL-C/HDL-C, TC/HDL-C, LDL-C/HDL-C, Apo-B/Apo-AI [Time Frame: from baseline at week 4, 8] The mean percent change of Fibrinogen, hs-CRP [Time Frame: from baseline at week 4, 8] Safety evaluation [Time Frame: Treatment period and Extension period]</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>&gt;19 years old High risk patient to Coronary Heart Disease (applied to 1 or more CHD risk factor listed below) 1. Patient with Coronary Heart Disease 2. Patient with carotid artery disease, peripheral blood vessel disease, abdominal aneurysm 3. Patient with diabetes(HbA1C≤9.0%) 4. 10year risk of CHD &gt;20%(by Framingham 10year risk score calculation) At Visit 1(Screening) 1. 100mg/dl≥LDLC, 150mg/dl≤TG≤500mg/dl 4weeks of Atorvastatin 20mg monotherapy runin period 2. LDLC&lt;100mg/dl, 150mg/dl≤TG≤500mg/dl If treated with Atorvastatin 20mg monotherapy 4weeks prior to this study At Visit 2(After 4weeks of Atorvastatin monotherapy runin period) LDL&lt;100mg/dl, 150mg/dl≤TG≤500mg/dl Patients with acute artery disease within 3 months Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrhythmia within 6 months Patients with uncontrolled hypertension(SBP&gt;160mmHg or DBP&gt;95mmHg) TSH&gt;1.5X ULN Patients with myopathy, rhabdomyolysis or CK&gt;2X ULN Hypersensitive to Atorvastatin and/or Fenofibrate or had photoallergy or phototoxicity during fibrate and/or ketoprofen treatment Serum Creatinine&gt;2.5mg/dl, AST or ALT &gt; 2X ULN History of drug or alcohol abuse within 6 months History of GI tract surgery or disability to drug absorption Women with pregnant, breastfeeding Patients with gallbladder disease Patients with biliary cirrhosis Patients with pancreatitis(acute pancreatitis is excluded due to severe hypertriglyceridemia) Patients treated with any investigational drugs within 4 weeks at the time consents are obtained History of malignant tumor including leukemia, lymphoma within 5 years Patients must be treated with medications prohibited for concomitant use during study period Not eligible to participate for the study at the discretion of investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>